AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25054648 — intervention group
Group type: COMPARATOR
Intervention: Extensible lumbosacral orthosis (eLSO)
Number of subjects: 98
Study 25054648 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard care (SC)
Number of subjects: 98
Study 22414352 — intervention group
Group type: EXPERIMENTAL
Intervention: Transpapillary injection
Number of subjects: 200
Study 22414352 — intervention group
Group type: COMPARATOR
Intervention: Conventional palatal injection
Number of subjects: 200
Study 20814766 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) intake (1.2-3.6 g/d)
Number of subjects: 0
Study 20814766 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) intake
Number of subjects: 0
Study 20814766 — intervention group
Group type: EXPERIMENTAL
Intervention: Observational evidence for ALA
Number of subjects: 0
Study 20814766 — intervention group
Group type: EXPERIMENTAL
Intervention: Alpha-linolenic acid (ALA) status
Number of subjects: 0
Study 17692522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy (5000lx, 100 cm distance)
Number of subjects: 11
Study 17692522 — intervention group
Group type: COMPARATOR
Intervention: Control group (natural lighting environment)
Number of subjects: 11
Study 17692522 — intervention group
Group type: EXPERIMENTAL
Intervention: Bright light therapy
Number of subjects: 11
Study 17692522 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 11
Study 15866495 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg AJA
Number of subjects: 21
Study 12469271 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-pro-BNP
Number of subjects: 150
Study 12469271 — intervention group
Group type: EXPERIMENTAL
Intervention: BNP
Number of subjects: 150
Study 10708321 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-delivered relapse prevention intervention
Number of subjects: 238
Study 10708321 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 238
Study 9187185 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 2.5 mg
Number of subjects: 10
Study 9187185 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 2.5 mg
Number of subjects: 10
Study 9187185 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg
Number of subjects: 10
Study 9187185 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 5 mg
Number of subjects: 10
Study 9187185 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg
Number of subjects: 10
Study 9187185 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER 10 mg
Number of subjects: 10
Study 9187185 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine
Number of subjects: 10
Study 9187185 — intervention group
Group type: EXPERIMENTAL
Intervention: Felodipine ER
Number of subjects: 10
Study 1414299 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 1% ophthalmic solution
Number of subjects: 56
Study 1414299 — intervention group
Group type: COMPARATOR
Intervention: Standard preoperative dilation regime
Number of subjects: 56
Study 2865930 — intervention group
Group type: EXPERIMENTAL
Intervention: PMP + D-penicillamine (DPA) - 500 mg/day
Number of subjects: 45
Study 2865930 — intervention group
Group type: EXPERIMENTAL
Intervention: PMP + sulphasalazine (SAS) - 2.0 g/day
Number of subjects: 45
Study 2865930 — intervention group
Group type: COMPARATOR
Intervention: PMP only
Number of subjects: 45
Study 30667283 — intervention group
Group type: EXPERIMENTAL
Intervention: NT-proBNP
Number of subjects: 1736
Study 30667283 — intervention group
Group type: EXPERIMENTAL
Intervention: Cystatin C
Number of subjects: 1736
Study 30667283 — intervention group
Group type: EXPERIMENTAL
Intervention: IL-6
Number of subjects: 1736
Study 28631896 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% Boric acid gel
Number of subjects: 48
Study 28631896 — intervention group
Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 48
Study 27379654 — intervention group
Group type: EXPERIMENTAL
Intervention: Iloperidone
Number of subjects: 303
Study 27379654 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 303
Study 24801644 — intervention group
Group type: EXPERIMENTAL
Intervention: Infusion set placed on the buttock
Number of subjects: 6
Study 24801644 — intervention group
Group type: COMPARATOR
Intervention: Infusion set placed on the abdomen
Number of subjects: 6
Study 22109950 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote video auditing with feedback
Number of subjects: 60542
Study 22109950 — intervention group
Group type: COMPARATOR
Intervention: Remote video auditing without feedback
Number of subjects: 60542
Study 20237221 — intervention group
Group type: EXPERIMENTAL
Intervention: Various proposed solutions to improve value in cancer care; specific interventions not detailed.
Number of subjects: 0
Study 19025668 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention (customized insoles, footwear advice, home-based exercise program, falls prevention education booklet)
Number of subjects: 300
Study 19025668 — intervention group
Group type: COMPARATOR
Intervention: Usual care (routine podiatry: nail care and callus debridement)
Number of subjects: 300
Study 19025668 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted podiatry intervention
Number of subjects: 300
Study 19025668 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 300
Study 16162440 — intervention group
Group type: EXPERIMENTAL
Intervention: Ciprofibrate treatment
Number of subjects: 29
Study 16162440 — intervention group
Group type: COMPARATOR
Intervention: Diet-only
Number of subjects: 29
Study 12941195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy using goserelin (LHRH agonist)
Number of subjects: 0
Study 12941195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy using bilateral orchiectomy
Number of subjects: 0
Study 12941195 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant hormone therapy using bicalutamide 150 mg
Number of subjects: 0
Study 12941195 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined androgen blockade (medical or surgical castration with antiandrogen)
Number of subjects: 0
Study 12941195 — intervention group
Group type: EXPERIMENTAL
Intervention: LHRH agonists (e.g., goserelin)
Number of subjects: 0
Study 12941195 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsteroidal antiandrogens
Number of subjects: 0
Study 10380836 — intervention group
Group type: EXPERIMENTAL
Intervention: Intermittent cyclical etidronate (400 mg daily for 2 weeks) and calcium (500 mg daily for 11 weeks)
Number of subjects: 28
Study 10380836 — intervention group
Group type: COMPARATOR
Intervention: Intermittent cyclical placebo with calcium
Number of subjects: 28
Study 8671814 — intervention group
Group type: COMPARATOR
Intervention: Diabetic patients at baseline
Number of subjects: 0
Study 8671814 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic subjects at follow-up
Number of subjects: 0
Study 8671814 — intervention group
Group type: EXPERIMENTAL
Intervention: Normoalbuminuric patients (UAER < 30mg/24 h)
Number of subjects: 0
Study 8671814 — intervention group
Group type: EXPERIMENTAL
Intervention: Microalbuminuric subjects
Number of subjects: 0
Study 8671814 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum insulin concentration
Number of subjects: 0
Study 8671814 — intervention group
Group type: EXPERIMENTAL
Intervention: Baseline serum insulin concentration and diuretic therapy
Number of subjects: 0
Study 2065824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive neurodevelopmental therapy (NDT)
Number of subjects: 73
Study 2065824 — intervention group
Group type: EXPERIMENTAL
Intervention: Upper-extremity inhibitive casting
Number of subjects: 73
Study 2065824 — intervention group
Group type: EXPERIMENTAL
Intervention: Casting with NDT
Number of subjects: 73
Study 2065824 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy alone
Number of subjects: 73
Study 2065824 — intervention group
Group type: COMPARATOR
Intervention: Regular therapy
Number of subjects: 73
Study 2065824 — intervention group
Group type: EXPERIMENTAL
Intervention: NDT plus casting
Number of subjects: 73
Study 30118533 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Implant Planning and Placement (CAIPP) - Test 1 (T1, n = 24)
Number of subjects: 73
Study 30118533 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-Assisted Implant Planning and Placement (CAIPP) - Test 2 (T2, n = 23)
Number of subjects: 73
Study 30118533 — intervention group
Group type: COMPARATOR
Intervention: Conventional protocol (C, n = 26)
Number of subjects: 73
Study 26806668 — intervention group
Group type: EXPERIMENTAL
Intervention: Minute ventilation-targeted adaptive servo-ventilation (MV-ASV) during sleep in addition to optimized medical therapy (active therapy)
Number of subjects: 126
Study 26806668 — intervention group
Group type: COMPARATOR
Intervention: Optimized medical therapy alone (usual care)
Number of subjects: 126
Study 25153328 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily liquorice consumption (glycyrrhizin dose 290‐370 mg) for two weeks
Number of subjects: 20
Study 25153328 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal diet)
Number of subjects: 20
Study 22774385 — intervention group
Group type: EXPERIMENTAL
Intervention: Community health workers (CHWs) intervention with a 16-hour training session and a 6-week tailored educational program.
Number of subjects: 0
Study 22774385 — intervention group
Group type: COMPARATOR
Intervention: Weekly lectures by clinical experts (Control group).
Number of subjects: 0
Study 19930245 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of propofol 2 mg/kg with supplemental doses of 0.5 mg/kg as needed, followed by normal saline infusion at 0.3 ml/kg/h.
Number of subjects: 160
Study 19930245 — intervention group
Group type: COMPARATOR
Intervention: Continuous infusion of propofol after initial sedation.
Number of subjects: 160
Study 18538243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed functional orthodontic appliance (Forsus nitinol flat‐spring, 3M Unitek Corp, Monrovia, Calif) for 7 months
Number of subjects: 60
Study 18538243 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 60
Study 18538243 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed functional orthodontic appliance
Number of subjects: 60
Study 16334716 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture combined with point-injection therapy
Number of subjects: 30
Study 16334716 — intervention group
Group type: COMPARATOR
Intervention: Basic neural medical treatment
Number of subjects: 30
Study 12185427 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure- and volume-limited ventilation
Number of subjects: 120
Study 10598967 — intervention group
Group type: EXPERIMENTAL
Intervention: AV node ablation and pacemaker implantation after discontinuation of rate-control medications
Number of subjects: 0
Study 10598967 — intervention group
Group type: EXPERIMENTAL
Intervention: AV node ablation and pacemaker implantation without discontinuation of antiarrhythmic rate-control drugs
Number of subjects: 0
Study 10598967 — intervention group
Group type: COMPARATOR
Intervention: Pacemaker implantation without AV node ablation and continuing rate-control medical therapy
Number of subjects: 0
Study 7564786 — intervention group
Group type: EXPERIMENTAL
Intervention: One-sided informed consent for randomisation
Number of subjects: 2035
Study 7564786 — intervention group
Group type: EXPERIMENTAL
Intervention: Two-sided informed consent for randomisation
Number of subjects: 2035
Study 7564786 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised consent to experimental treatment
Number of subjects: 2035
Study 7564786 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomised consent to standard treatment
Number of subjects: 2035
Study 2009781 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose amrinone (0.75 mg/kg loading dose + 10 micrograms/kg/min infusion)
Number of subjects: 24
Study 2009781 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose amrinone (2.25 mg/kg loading dose + 20 micrograms/kg/min infusion)
Number of subjects: 24
Study 7120373 — intervention group
Group type: COMPARATOR
Intervention: 0% feedback schedule
Number of subjects: 36
Study 7120373 — intervention group
Group type: EXPERIMENTAL
Intervention: 25% feedback schedule
Number of subjects: 36
Study 7120373 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% feedback schedule
Number of subjects: 36
Study 7120373 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback at left arm
Number of subjects: 36
Study 7120373 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback at both arms
Number of subjects: 36
Study 7120373 — intervention group
Group type: EXPERIMENTAL
Intervention: Feedback at right arm
Number of subjects: 36
Study 30919382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early P2Y12 inhibitor loading (clopidogrel)
Number of subjects: 60907
Study 30919382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clopidogrel loading
Number of subjects: 60907
Study 30919382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clopidogrel loading in ST-elevation myocardial infarction
Number of subjects: 60907
Study 30919382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early clopidogrel loading in non-ST elevation acute coronary syndrome (NSTE-ACS)
Number of subjects: 60907
Study 30919382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early loading with prasugrel and ticagrelor
Number of subjects: 60907
Study 30919382 — intervention group
Group type: EXPERIMENTAL
Intervention: Early prasugrel loading in NSTE-ACS
Number of subjects: 60907
Study 30919382 — intervention group
Group type: EXPERIMENTAL
Intervention: Timing of ticagrelor or prasugrel loading
Number of subjects: 60907
Study 29975953 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus chemotherapy (CAG regimen with thalidomide at a maximum dose of 200 mg/day)
Number of subjects: 70
Study 29975953 — intervention group
Group type: COMPARATOR
Intervention: Control arm (PC) - non‐intensive regimen composed of cytarabine, aclarubicin and G‐CSF (CAG) chemotherapy
Number of subjects: 70
Study 29975953 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalidomide plus chemotherapy
Number of subjects: 70
Study 29975953 — intervention group
Group type: COMPARATOR
Intervention: Control arm (PC)
Number of subjects: 70
Study 26173850 — intervention group
Group type: EXPERIMENTAL
Intervention: Roux-en-Y gastric bypass (RYGB)
Number of subjects: 60
Study 26173850 — intervention group
Group type: EXPERIMENTAL
Intervention: Biliopancreatic diversion with duodenal switch (DS)
Number of subjects: 60
Study 26173850 — intervention group
Group type: COMPARATOR
Intervention: Objective bulimic episodes before surgery
Number of subjects: 60
Study 24739131 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day for 8 weeks
Number of subjects: 52
Study 24739131 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 20 mg/day for 8 weeks
Number of subjects: 52
Study 24739131 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 10 mg/day and 20 mg/day for 8 weeks
Number of subjects: 52
Study 24739131 — intervention group
Group type: COMPARATOR
Intervention: Control group (healthy subjects)
Number of subjects: 52
Study 22824595 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative subconjunctival injection of mitomycin C (0.1 ml of 0.15 mg/ml) a day before surgery
Number of subjects: 50
Study 22824595 — intervention group
Group type: COMPARATOR
Intervention: Topical application of mitomycin C during surgery (same concentration)
Number of subjects: 50
Study 22824595 — intervention group
Group type: EXPERIMENTAL
Intervention: Preoperative subconjunctival injection of mitomycin C
Number of subjects: 50
Study 19015231 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjunctive antidepressant treatment for bipolar depression
Number of subjects: 176
Study 17192668 — intervention group
Group type: EXPERIMENTAL
Intervention: Ispronicline (TC‐1734)
Number of subjects: 0
Study 12740744 — intervention group
Group type: EXPERIMENTAL
Intervention: Tennis training and competition
Number of subjects: 17
Study 12740744 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 hour of tennis play
Number of subjects: 17
Study 12740744 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous day and week training
Number of subjects: 17
Study 12740744 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise-induced suppression of salivary IgA
Number of subjects: 17
Study 11000297 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast spin-echo (FSE) sequence with effective TE of 20 ms
Number of subjects: 100
Study 11000297 — intervention group
Group type: COMPARATOR
Intervention: Conventional spin-echo (CSE) sequence
Number of subjects: 100
Study 8982148 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyurea (HU) therapy
Number of subjects: 0
Study 8982148 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 1597230 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin infusion (100 micrograms.min‐1)
Number of subjects: 0
Study 1597230 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6233404 — intervention group
Group type: EXPERIMENTAL
Intervention: Tc-99m HMDP
Number of subjects: 28
Study 6233404 — intervention group
Group type: COMPARATOR
Intervention: Tc-99m MDP
Number of subjects: 28
Study 30312459 — intervention group
Group type: EXPERIMENTAL
Intervention: Living Better Beyond Pain (LBBP) program
Number of subjects: 35
Study 31374191 — intervention group
Group type: EXPERIMENTAL
Intervention: Monthly coaching by physiotherapists encouraging 30 minutes of daily physical activity and 45-60 minutes of weekly exercise
Number of subjects: 186
Study 25638011 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 30 mg/kg IV
Number of subjects: 37
Study 25638011 — intervention group
Group type: EXPERIMENTAL
Intervention: secukinumab 10 mg/kg IV
Number of subjects: 37
Study 25638011 — intervention group
Group type: COMPARATOR
Intervention: secukinumab 300 mg SC
Number of subjects: 37
Study 23649562 — intervention group
Group type: EXPERIMENTAL
Intervention: Loving-kindness meditation intervention group
Number of subjects: 0
Study 23649562 — intervention group
Group type: COMPARATOR
Intervention: Waiting-list control group
Number of subjects: 0
Study 21617456 — intervention group
Group type: EXPERIMENTAL
Intervention: Arginine
Number of subjects: 20
Study 21617456 — intervention group
Group type: COMPARATOR
Intervention: Alanine (control)
Number of subjects: 20
Study 18830553 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive local analgesia (PLA) with 20 ml of 0.5% bupivacaine with 1:200,000 epinephrine
Number of subjects: 90
Study 18830553 — intervention group
Group type: EXPERIMENTAL
Intervention: Preemptive local analgesia (PLA)
Number of subjects: 90
Study 16984502 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated-interferon-alpha2a plus ribavirin
Number of subjects: 161
Study 16984502 — intervention group
Group type: COMPARATOR
Intervention: Pegylated-interferon-alpha2a plus ribavirin and amantadine
Number of subjects: 161
Study 15035516 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mL of iopamidol (300 mgI/mL) at 5 mL/second
Number of subjects: 23
Study 15035516 — intervention group
Group type: COMPARATOR
Intervention: 100 mL of iopamidol (370 mgI/mL) at 4 mL/second
Number of subjects: 23
Study 11488732 — intervention group
Group type: EXPERIMENTAL
Intervention: Interstitial radiofrequency therapy (IRFT)
Number of subjects: 2
Study 11488732 — intervention group
Group type: COMPARATOR
Intervention: Transurethral resection of the prostate (TURP)
Number of subjects: 2
Study 11488732 — intervention group
Group type: EXPERIMENTAL
Intervention: Both IRFT and TURP
Number of subjects: 2
Study 9743440 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine GITS (30 mg starting dose, 60 mg maintenance dose once daily)
Number of subjects: 6000
Study 9743440 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 6000
Study 8039525 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged cognitive task prior to sleep onset
Number of subjects: 14
Study 8039525 — intervention group
Group type: COMPARATOR
Intervention: Relaxing condition (staying awake in a relaxed state)
Number of subjects: 14
Study 2737602 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine with HBsAg complexed by anti-HBs in hepatitis B immunoglobulin at equivalent proportions
Number of subjects: 305
Study 2737602 — intervention group
Group type: EXPERIMENTAL
Intervention: Heat-inactivated hepatitis B vaccine with HBsAg complexed by anti-HBs in hepatitis B immunoglobulin at 10-fold antigen excess
Number of subjects: 305
Study 2737602 — intervention group
Group type: COMPARATOR
Intervention: Control vaccine with standard dosage of HBsAg (3 micrograms)
Number of subjects: 305
Study 29625841 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant gemcitabine 1000 mg/m2 on days 1, 8, 15 every 4 weeks for six cycles (group A)
Number of subjects: 88
Study 29625841 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant PEXG (cisplatin 30 mg/m2, epirubicin 30 mg/m2, and gemcitabine 800 mg/m2 on days 1 and 15 every 4 weeks and capecitabine 1250 mg/m2 on days 1-28) (group B)
Number of subjects: 88
Study 29625841 — intervention group
Group type: EXPERIMENTAL
Intervention: Three cycles of PEXG before and three cycles after surgery (group C)
Number of subjects: 88
Study 29625841 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 88
Study 29625841 — intervention group
Group type: EXPERIMENTAL
Intervention: Toxicity analysis for all groups
Number of subjects: 88
Study 28126156 — intervention group
Group type: EXPERIMENTAL
Intervention: Coronary artery bypass graft (CABG)
Number of subjects: 1550
Study 28126156 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous coronary intervention (PCI)
Number of subjects: 1550
Study 28126156 — intervention group
Group type: COMPARATOR
Intervention: Medical therapy
Number of subjects: 1550
Study 26328588 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI) therapy with 40 mg pantoprazole b.i.d.
Number of subjects: 24
Study 26328588 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 24
Study 22699302 — intervention group
Group type: EXPERIMENTAL
Intervention: Anamorelin 50 mg/day
Number of subjects: 16
Study 22699302 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 21714844 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured educational nursing intervention (6 hours of instruction and 2 hours of clinical demonstration)
Number of subjects: 192